Fialkow P J, Klein E, Klein G, Clifford P, Singh S
J Exp Med. 1973 Jul 1;138(1):89-102. doi: 10.1084/jem.138.1.89.
Two independent marker systems, G-6-PD isoenzymes and cell membrane-associated IgM, were used to trace the cellular origin of Burkitt lymphoma. Application of the G-6-PD system is dependent upon the fact that, in accordance with inactivity of one X chromosome in each somatic cell, females heterozygous for the usual B gene (Gd(B)) at the X-linked G-6-PD locus and the variant allele Gd(A) (or Gd(A-)) have two types of cells. Gd(B) is active in one cell population, which consequently produces B type enzyme; in the other population Gd(A) is active, producing the variant A enzyme. Therefore, tumors with a clonal origin in a Gd(B)/Gd(A) heterozygote should exhibit only one enzyme type (B or A) whereas those with multicellular origin may show both A and B enzymes. Utilization of the immunoglobulin system is based upon the supposition that in lymphoid neoplasms with clonal origin either all or none of the tumor cells should have surface-associated IgM and kappa-reactivities. 33 of 34 relatively homogeneous (with respect to content of neoplastic cells) individual Burkitt tumors from 19 G-6-PD heterozygotes had single enzyme phenotypes. Similarly, of 95 tumors tested, 92 consisted essentially of IgM(+) or (-) cells. Two neoplasms could not be definitely classified and one tumor had two cell populations. These data suggest a clonal origin for most Burkitt tumors, but the one neoplasm with a double G-6-PD phenotype (A/B) and the one tumor that had two populations of cells with respect to surface IgM, could have originated from multiple cells. G-6-PD was determined in each of two tumors from seven heterozygotes and in all cases both tumors had the same single enzyme phenotype. Surface-associated IgM was tested in four tumors from one patient, three from another, and in two neoplasms from 11 patients. With one exception, all tumors from the same patient were concordant with respect to IgM. These findings suggest that the entire disease has a clonal origin, i.e., it emerges at one focus and then spreads to other parts of the body. Cells from 36 recurrent neoplasms were typed for G-6-PD (in heterozygotes) and/or IgM. In one previously reported patient, initial and recurrent tumors were discordant for G-6-PD. Two other patients had IgM phenotypes in recurrences that were discordant with those found in their initial tumors. Phenotypes from three of nine relapses which occurred after 5 mo were discordant for G-6-PD or IgM but no discordance was detected among 27 earlier recurrences. Thus, some "late" recurrences may be due to emergence of "new" maligant cell lines whereas most early relapses are due to reemergence of the original malignant clones. The probable unicellular origin of Burkitt lymphoma and the findings in tumor recurrences are discussed in terms of the disease's putative viral etiology.
使用两种独立的标记系统,即葡萄糖-6-磷酸脱氢酶(G-6-PD)同工酶和细胞膜相关免疫球蛋白M(IgM),来追踪伯基特淋巴瘤的细胞起源。G-6-PD系统的应用基于这样一个事实,即根据每个体细胞中一条X染色体的失活情况,在X连锁的G-6-PD位点上,对于常见的B基因(Gd(B))和变异等位基因Gd(A)(或Gd(A-))呈杂合状态的女性有两种细胞类型。Gd(B)在一个细胞群体中是活跃的,因此该群体产生B型酶;在另一个群体中Gd(A)是活跃的,产生变异的A型酶。所以,在Gd(B)/Gd(A)杂合子中起源于克隆的肿瘤应该只表现出一种酶类型(B或A),而那些起源于多个细胞的肿瘤可能同时显示A和B两种酶。免疫球蛋白系统的应用基于这样的假设,即在起源于克隆细胞的淋巴肿瘤中,所有肿瘤细胞要么都有表面相关IgM和κ反应性,要么都没有。来自19名G-6-PD杂合子的34个相对均质(就肿瘤细胞含量而言)的单个伯基特肿瘤中,有33个具有单一酶表型。同样,在检测的95个肿瘤中,92个基本上由IgM(+)或(-)细胞组成。有两个肿瘤无法明确分类,一个肿瘤有两个细胞群体。这些数据表明大多数伯基特肿瘤起源于克隆,但那个具有双重G-6-PD表型(A/B)的肿瘤以及那个在表面IgM方面有两个细胞群体的肿瘤,可能起源于多个细胞。在来自7名杂合子的两个肿瘤中分别测定了G-6-PD,在所有情况下,两个肿瘤都具有相同的单一酶表型。在一名患者的4个肿瘤、另一名患者的3个肿瘤以及来自11名患者的2个肿瘤中检测了表面相关IgM。除了一个例外,来自同一患者的所有肿瘤在IgM方面都是一致的。这些发现表明整个疾病起源于克隆,也就是说,它在一个病灶处出现,然后扩散到身体的其他部位。对36个复发性肿瘤的细胞进行了G-6-PD(在杂合子中)和/或IgM分型。在一名先前报道的患者中,初始肿瘤和复发性肿瘤在G-6-PD方面不一致。另外两名患者复发性肿瘤的IgM表型与初始肿瘤中发现的表型不一致。在5个月后发生的9次复发中有3次的表型在G-6-PD或IgM方面不一致,但在27次较早的复发中未检测到不一致情况。因此,一些“晚期”复发可能是由于“新的”恶性细胞系的出现,而大多数早期复发是由于原始恶性克隆的再次出现。根据该疾病假定的病毒病因学,讨论了伯基特淋巴瘤可能的单细胞起源以及肿瘤复发的情况。